Catalyst for Expansion: Regulatory Shifts and the Modernization Act A major growth driver in 2026 is the maturity of the FDA Modernization Act 2.0. This legislation has officially removed the federal mandate for animal testing for new drug applications, provided that alternative methods are validated. The US Preclinical CRO Market growth is currently fueled by the "Validation Race," where CROs are competing to prove the efficacy of their 3D-bioprinted human tissue models to the FDA. https://www.marketresearchfuture.com/reports/us-preclinical-cro-market-49336 Another significant catalyst is the "Reshoring of R&D." Amid geopolitical tensions and supply chain concerns regarding overseas non-human primates (NHPs), many US pharmaceutical companies are moving their preclinical work back to domestic CROs. This "Onshoring" trend has led to a capacity crunch in the US, driving major CROs to invest in Automated Bio-Banking and high-throughput screening facilities to handle the increased domestic volume. FAQ: Question: What is the FDA Modernization Act 2.0? Answer: A law that allows drug developers to use non-animal testing methods (like cell-based assays or computer models) to prove safety before clinical trials. Question: Why are companies moving research back to the US? Answer: To ensure supply chain security and closer collaboration with regulatory bodies during the preclinical phase.